Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapies that harness the body’s protein homeostasis pathways. The company’s core technology platform centers on modulating E3 ubiquitin ligases to selectively degrade disease-causing proteins. By leveraging its proprietary targeted protein degradation approach, Nurix aims to address both oncology and immunology indications with high unmet medical need.
The company’s development pipeline includes multiple oral candidates. Lead programs include NX-2127, a Bruton’s tyrosine kinase (BTK) degrader in clinical trials for B-cell malignancies, and NX-1607, an immuno-oncology asset designed to enhance T-cell activity against solid tumors. Nurix has established strategic collaborations to broaden its research scope, notably partnering with GlaxoSmithKline on immunology programs and with Janssen to advance select oncology applications. These alliances extend the company’s expertise and accelerate progression of its targeted degradation portfolio.
Founded in 2016 and headquartered in San Francisco, California, Nurix operates research and development facilities in the United States. Its clinical studies span North America and select international sites, reflecting a commitment to global patient access. The company’s scientific founders and research teams have drawn on decades of ubiquitin pathway research to build a robust pipeline of differentiated drug candidates.
Leadership at Nurix includes Troy E. Wilson, Ph.D., serving as Chief Executive Officer, and a management team with deep experience in biopharmaceutical development. Under their guidance, the company continues to advance its modular platform, seeking partnerships and exploring additional therapeutic areas where targeted protein degradation may offer transformative benefits.
AI Generated. May Contain Errors.
Free NRIX Stock Alerts